Shennon Biotechnologies is developing precision immunotherapies for solid tumors through an integrated technology platform spanning target discovery, ultra-high-throughput microfluidics-driven functional screening, computational binder design and predictive safety assessment. In particular, where conventional discovery tests binders sequentially over months, Shennon’s functional screening platform TCELERATOR^TM profiles more than 10 million single-cell interactions at once, identifying functional leads in a single experiment. The unified engine is supported by proprietary human tumor datasets and an expanding network of academic and clinical collaborators. The Company is developing both antibody-based and TCR-based T-cell engagers designed to address surface and intracellular cancer targets. Its initial oncology pipeline includes programs in small cell lung cancer, ovarian cancer and hepatocellular carcinoma. ShennonBio is based in San Francisco.